Korro to Participate in Upcoming September Investor and Scientific Conferences
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced its participation in several upcoming investor and scientific conferences in September 2024. These include:
1. 2024 Wells Fargo Healthcare Conference (Sept. 4): 1x1 investor meetings
2. RNA Leaders USA Congress (Sept. 5): Presentation on OPERA™ platform
3. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9): Company presentation
4. ISCTM 2024 Autumn Conference (Sept. 12): Session on neurophysiological markers
The H.C. Wainwright presentation will be webcast live and available for replay on Korro's website for 30 days.
Korro Bio, Inc. (Nasdaq: KRRO), una società biopharmaceutica che sviluppa medicinali genetici mediante editing dell'RNA, ha annunciato la sua partecipazione a diverse conferenze per investitori e scientifiche che si terranno a settembre 2024. Queste includono:
1. Conferenza Sanitaria Wells Fargo 2024 (4 settembre): incontri individuali con gli investitori
2. Congresso RNA Leaders USA (5 settembre): presentazione sulla piattaforma OPERA™
3. 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright (9 settembre): presentazione aziendale
4. Conferenza Autunnale ISCTM 2024 (12 settembre): sessione sui marcatori neurofisiologici
La presentazione di H.C. Wainwright sarà trasmessa in diretta e disponibile per la visione in seguito sul sito di Korro per 30 giorni.
Korro Bio, Inc. (Nasdaq: KRRO), una empresa biofarmacéutica que desarrolla medicamentos genéticos mediante edición de RNA, anunció su participación en varias conferencias para inversores y científicas que se llevarán a cabo en septiembre de 2024. Estas incluyen:
1. Conferencia de Atención Médica Wells Fargo 2024 (4 de septiembre): reuniones individuales con inversores
2. Congreso Líderes de RNA EE.UU. (5 de septiembre): presentación sobre la plataforma OPERA™
3. 26ª Conferencia Anual Global de Inversiones H.C. Wainwright (9 de septiembre): presentación de la empresa
4. Conferencia Otoñal ISCTM 2024 (12 de septiembre): sesión sobre marcadores neurofisiológicos
La presentación de H.C. Wainwright se transmitirá en vivo y estará disponible para volver a ver en el sitio web de Korro durante 30 días.
코로 바이오, 인크. (Nasdaq: KRRO)는 RNA 편집 유전자 의약품을 개발하는 생명공학 회사로, 2024년 9월에 열리는 여러 투자자 및 과학 회의에 참여할 것이라고 발표했습니다. 이 회의에는 다음이 포함됩니다:
1. 2024 웰스파고 헬스케어 컨퍼런스 (9월 4일): 1x1 투자자 미팅
2. RNA 리더스 USA 회의 (9월 5일): OPERA™ 플랫폼에 대한 발표
3. H.C. 웨인라이트 제26회 연례 글로벌 투자 회의 (9월 9일): 회사 발표
4. ISCTM 2024 가을 회의 (9월 12일): 신경생리학적 마커 세션
H.C. 웨인라이트 발표는 라이브로 웹캐스트되며, 코로의 웹사이트에서 30일 동안 재생할 수 있습니다.
Korro Bio, Inc. (Nasdaq: KRRO), une entreprise biopharmaceutique développant des médicaments génétiques par édition de l'ARN, a annoncé sa participation à plusieurs conférences pour investisseurs et scientifiques prévues en septembre 2024. Celles-ci incluent :
1. Conférence de Santé Wells Fargo 2024 (4 septembre) : réunions individuelles avec des investisseurs
2. Congrès RNA Leaders USA (5 septembre) : présentation sur la plateforme OPERA™
3. 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright (9 septembre) : présentation de l'entreprise
4. Conférence d'Automne ISCTM 2024 (12 septembre) : session sur les marqueurs neurophysiologiques
La présentation de H.C. Wainwright sera diffusée en direct et disponible en replay sur le site de Korro pendant 30 jours.
Korro Bio, Inc. (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen, das RNA-bearbeitende Gentherapien entwickelt, gab seine Teilnahme an mehreren bevorstehenden Investoren- und Wissenschaftskonferenzen im September 2024 bekannt. Dazu gehören:
1. 2024 Wells Fargo Gesundheitskonferenz (4. September): 1x1 Investorengespräche
2. RNA Leaders USA Kongress (5. September): Präsentation zur OPERA™-Plattform
3. 26. jährliche globale Investorenkonferenz von H.C. Wainwright (9. September): Unternehmenspräsentation
4. ISCTM 2024 Herbstkonferenz (12. September): Sitzung zu neurophysiologischen Markern
Die Präsentation von H.C. Wainwright wird live übertragen und ist für 30 Tage auf der Website von Korro verfügbar.
- None.
- None.
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences:
2024 Wells Fargo Healthcare Conference
Chief Executive Officer and President, Ram Aiyar, Ph.D., and Chief Financial Officer, Vineet Agarwal, will participate in 1x1 investor meetings on Wednesday, September 4, 2024.
RNA Leaders USA Congress
Chief Operating Officer, Todd Chappell, will discuss the benefits of Korro’s OPERA™ platform in a presentation titled “Using a Novel ADAR Editing Platform to Address Unmet Needs in Liver and CNS Therapeutics” on Thursday, September 5, 2024, at 9:00 a.m. ET.
H.C. Wainwright 26th Annual Global Investment Conference
Dr. Aiyar will present on Monday, September 9, 2024, at 12:30 p.m. ET. Mr. Agarwal will also be participating at the conference.
International Society for CNS Clinical Trials and Methodology (ISCTM) 2024 Autumn Conference
Chief Medical Officer, Kemi Olugemo, M.D., FANN, will participate in a session titled “Use of neurophysiological markers to design and enrich clinical trials in rare neurological disorders” on Thursday, September 12, 2024, at 8:30 a.m. ET.
The live webcast of the H.C. Wainwright presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
What conferences is Korro Bio (KRRO) attending in September 2024?
When is Korro Bio's (KRRO) presentation at the H.C. Wainwright conference?
What will Korro Bio (KRRO) discuss at the RNA Leaders USA Congress?
How can investors access Korro Bio's (KRRO) H.C. Wainwright presentation?
